Connect Biopharma Holdings Ltd (CNTB) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.31

From 52W high−65.31%

Volume1.27M

Market cap$80.61M

P/E (TTM)—

P/S (TTM)27.4x

Div yield—

Key dataSep 18, 2026

Open

$1.31

From 52W high

−65.31%

Volume

1.27M

Market cap

$80.61M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.0x

P/E (TTM)

—

RSI (14)

33.0

MomentumView details →

1D Return

−0.78%

YTD Return

−54.08%

SummaryUpdated Jun 1, 2026

Connect Biopharma Holdings Limited (NASDAQ:CNTB) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Taicang, China. The company went public in March 2021 and focuses on discovering and developing immune modulators for treating serious autoimmune diseases and inflammatory conditions. Connect Biopharma operates in the highly specialized biotechnology sector, where companies typically spend years and hundreds of millions of dollars developing drug candidates through rigorous clinical trials before potentially bringing treatments to market.

Ask drillr about Connect Biopharma Holdings Ltd →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.0x

EV/Sales

16.9x

P/S (TTM)

27.4x

P/B (TTM)

3.0x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−1763.40%

EBITDA Margin

−1763.26%

ROE (TTM)

−192.81%

ROA (TTM)

−119.14%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

+293.70%

EPS YoY

−35.38%

FCF YoY

−10.92%

Revenue CAGR 3Y

−99.75%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−0.78%

YTD Return

−54.08%

1Y Return

−17.52%

RSI (14)

33.0

vs 50D SMA

−39.73%

vs 200D SMA

−46.45%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

2.37x

Quick Ratio

2.37x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.27

EPS Surprise

14.26%

Beats (12Q)

9/12

Next Q EPS Est

−$0.23

Avg Surprise (4Q)

0.62%

Rev Surprise

269.69%

Financials snapshotView financials →

Revenue (TTM)

3.68M

Net Income (TTM)

−73.60M

Op. CF (TTM)

−71.35M

Next earningsNov 11, 2026 →

Latest newsMore news →

Connect Biopharma Holdings Limited released topline results from its global Phase 2 study evaluating rademikibart, sending its stock to a 52-week low on Tuesday.5d ago

Connect Biopharma Holdings Limited reported financial results for the second quarter of 2026, ending June 30, 2026.39d ago

Similar companies

iBio, Inc.IBIO Acrivon Therapeutics, Inc. Common StockACRV Aldeyra Therapeutics, Inc.ALDX Yarrow Bioscience IncYARW Fortress Biotech, Inc.FBIO Gain Therapeutics, Inc.GANX Find similar companies →

Latest newsMore news →

Connect Biopharma Holdings Limited released topline results from its global Phase 2 study evaluating rademikibart, sending its stock to a 52-week low on Tuesday.5d ago Connect Biopharma Holdings Limited reported financial results for the second quarter of 2026, ending June 30, 2026.39d ago